Migraine – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis Migraine (Acute)
Triptans have long been the mainstay of acute treatment of migraine, but in Q1 2020, three novel oral nontriptans—Eli Lilly’s Reyvow, AbbVie / Allergan’s Ubrelvy, and Biohaven’s Nurtec ODT—entered the U.S. market. These therapies offer clinically distinct alternatives to triptans, particularly for patients who cannot tolerate, are contraindicated, or do not adequately respond to triptans. In this report, we leverage national patient-level claims data to assess the relative uptake and performance of these new brands versus the standard of care. Understanding the treatment paradigms and patient flow will provide needed context for developers entering a heavily generic and increasingly saturated market.
QUESTIONS ANSWERED
- What patient shares do key acute therapies garner by line of therapy in newly diagnosed migraine patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed migraine patients?
- What is the dynamic between Reyvow, Ubrelvy, and Nurtec ODT? How have they been integrated into practice, and what are their sources of business?
- What percentage of migraine patients began acute drug therapy during our two-year prescription-tracking period? What percentage of patients progress to later lines of therapy, and how quickly do they progress?
- What percentage of migraine patients are treated with monotherapy versus combination therapy for acute attacks? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated migraine patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Eli Lilly, AbbVie / Allergan, Biohaven Pharmaceuticals, Upsher-Smith, Currax Pharmaceuticals
Key drugs: Reyvow, Ubrelvy, Nurtec ODT, Onzetra Xsail, Tosymra, Zembrace SymTouch, generic triptans, ergot derivatives, Cambia
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, and expanded analyses.
Table of contents
- Migraine - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis Migraine (Acute)
- Treatment Algorithms CDA Migraine (Acute) US June 2021
- Treatment Algorithms CDA Migraine (Acute) US 2021 Dashboard
Jonathan W. Searles is a senior director on the CNS/Ophthalmology Disorders team at Clarivate. In this role, he oversees the team’s syndicated research stream in neurology, with a core focus on multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, epilepsy, migraine, and ischemic stroke. He earned his bachelor’s degree at Brandeis University, where he graduated summa cum laude.